ClinicalTrials.gov record
Active, not recruiting Phase 1Phase 2 Interventional Results available

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

ClinicalTrials.gov ID: NCT04216316

Public ClinicalTrials.gov record NCT04216316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IB and Randomized Open-Label Phase II Study of Berzosertib (M6620, VX-970) in Combination With Carboplatin/Gemcitabine/Pembrolizumab in Patients With Chemotherapy-Naïve Advanced Non-Small Cell Lung Cancer of Squamous Cell Histology

Study identification

NCT ID
NCT04216316
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
12 participants

Conditions and interventions

Interventions

  • Berzosertib Drug
  • Biospecimen Collection Procedure
  • Carboplatin Drug
  • Computed Tomography Procedure
  • Gemcitabine Hydrochloride Drug
  • Magnetic Resonance Imaging Procedure
  • Pembrolizumab Biological

Drug · Procedure · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 13, 2021
Primary completion
Mar 30, 2024
Completion
Mar 17, 2027
Last update posted
Apr 12, 2026

2021 – 2027

United States locations

U.S. sites
34
U.S. states
9
U.S. cities
28
Facility City State ZIP Site status
Keck Medicine of USC Koreatown Los Angeles California 90020
Los Angeles General Medical Center Los Angeles California 90033
USC / Norris Comprehensive Cancer Center Los Angeles California 90033
USC Norris Oncology/Hematology-Newport Beach Newport Beach California 92663
UM Sylvester Comprehensive Cancer Center at Aventura Aventura Florida 33180
UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables Florida 33146
UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach Florida 33442
University of Miami Miller School of Medicine-Sylvester Cancer Center Miami Florida 33136
University of Kansas Clinical Research Center Fairway Kansas 66205
HaysMed Hays Kansas 67601
University of Kansas Cancer Center Kansas City Kansas 66160
Lawrence Memorial Hospital Lawrence Kansas 66044
The University of Kansas Cancer Center - Olathe Olathe Kansas 66061
University of Kansas Cancer Center-Overland Park Overland Park Kansas 66210
University of Kansas Hospital-Indian Creek Campus Overland Park Kansas 66211
Mercy Hospital Pittsburg Pittsburg Kansas 66762
Salina Regional Health Center Salina Kansas 67401
University of Kansas Health System Saint Francis Campus Topeka Kansas 66606
University of Kansas Hospital-Westwood Cancer Center Westwood Kansas 66205
Siteman Cancer Center at Saint Peters Hospital City of Saint Peters Missouri 63376
Siteman Cancer Center at West County Hospital Creve Coeur Missouri 63141
University Health Truman Medical Center Kansas City Missouri 64108
University of Kansas Cancer Center - North Kansas City Missouri 64154
University of Kansas Cancer Center - Lee's Summit Lee's Summit Missouri 64064
University of Kansas Cancer Center at North Kansas City Hospital North Kansas City Missouri 64116
Washington University School of Medicine St Louis Missouri 63110
Siteman Cancer Center-South County St Louis Missouri 63129
Siteman Cancer Center at Christian Hospital St Louis Missouri 63136
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center Lebanon New Hampshire 03756
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center New York New York 10032
Wake Forest University at Clemmons Clemmons North Carolina 27012
Wake Forest University Health Sciences Winston-Salem North Carolina 27157
University of Pittsburgh Cancer Institute (UPCI) Pittsburgh Pennsylvania 15232
VCU Massey Comprehensive Cancer Center Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04216316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 12, 2026 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04216316 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →